Fennec Pharmaceuticals (FENC) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 14, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'ADHXF	'	'
Entity Common Stock, Shares Outstanding	'	29,307,618	'
Entity Registrant Name	'ADHEREX TECHNOLOGIES INC	'	'
Entity Central Index Key	'0001211583	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$2,802,147

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$1,663	$2,303
Prepaid expense	81	56
Other current assets	8	6
Total assets	1,752	2,365
Current liabilities	'	'
Accounts payable	212	259
Accrued liabilities	132	423
Derivative liabilities	2,863	6,640
Total current liabilities	3,207	7,322
Total liabilities	3,207	7,322
Commitments and contingencies (Note 8)	'	'
Stockholders' (deficit) equity	'	'
Common stock, no par value; unlimited shares authorized; (2013 - 29,158, 2012 - 25,158 shares issued and outstanding)	66,790	65,952
Additional paid-in capital	39,210	38,391
Deficit accumulated during development stage	-108,698	-110,543
Accumulated other comprehensive income	1,243	1,243
Total stockholders' (deficit) equity	-1,455	-4,957
Total liabilities and stockholders' (deficit) equity	$1,752	$2,365

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Common stock, no par value	$0	$0
Common stock, shares issued	29,158	25,158
Common stock, shares outstanding	29,158	25,158

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		208 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	$0	$0	$0
Operating expenses:	'	'	'
Research and development	597	2,075	69,765
Impairment of capital assets	0	0	386
Gain on deferred lease inducements	0	0	-497
Acquired in-process research and development	0	0	13,094
General and administration	1,334	1,545	33,428
Loss from operations	-1,931	-3,620	-116,176
Other income (expense):	'	'	'
Gain/(loss) on derivative warrants	3,777	-1,563	7,034
Settlement of Cadherin Biomedical Inc. litigation	0	0	-1,283
Interest expense	0	0	-19
Other (expense)/income	-3	-5	256
Interest income	2	25	2,899
Total other income/(expense)	3,776	-1,543	8,887
Net income/(loss) and total comprehensive income/(loss)	$1,845	($5,163)	($107,289)
Earnings/(loss) per share of common stock, basic (In dollars per share)	$0.06	($0.21)	'
Earnings/(loss) per share of common stock, diluted (In dollars per share)	$0.06	($0.21)	'
Weighted-average number of shares of common stock outstanding, basic (In shares)	29,158	25,158	'
Weighted-average number of shares of common stock outstanding, diluted (In shares)	31,714	25,158	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating activities:	'	'	'
Net income/(loss)	$1,845	($5,163)	($107,289)
Adjustments for non-cash items:	'	'	'
(Gain)/Loss on derivative warrants	-3,777	1,563	-7,034
Depreciation and amortization	0	0	1,404
Non-cash Cadherin Biomedical Inc. litigation expense	0	0	1,187
Unrealized foreign exchange loss	'	0	36
Loss on impairment of capital assets	0	0	386
Amortization of and gain on lease inducements	0	0	-412
Non-cash severance expense	0	0	168
Stock options issued to consultants	25	152	1,073
Stock options issued to employees	62	174	10,331
Acquired in-process research and development	0	0	13,094
Changes in non-cash working capital	-365	280	-191
Net cash used in operating activities	-2,210	-2,994	-87,247
Investing activities:	'	'	'
Purchase of capital assets	0	0	-1,440
Disposal of capital assets	0	0	115
Proceeds from sale of assets	0	0	24
Release of restricted cash	0	0	190
Restricted cash	0	0	-209
Purchase of short-term investments	0	0	-22,148
Redemption of short-term investments	0	0	22,791
Investment in Cadherin Biomedical Inc.	0	0	-166
Acquired intellectual property rights	0	0	-640
Net cash used in investing activities	0	0	-1,483
Financing activities:	'	'	'
Conversion of long-term debt to equity	0	0	68
Long-term debt repayments	0	0	-65
Capital lease repayments	0	0	-8
Issuance of common stock	1,570	0	88,013
Registration expense	0	0	-465
Financing expenses	0	0	-544
Proceeds from convertible note	0	0	3,017
Other liability repayments	0	0	-87
Security deposits received	0	0	35
Proceeds from exercise of stock options	0	0	51
Net cash provided from financing activities	1,570	0	90,015
Effect of exchange rate changes on cash and cash equivalents	0	0	378
Net change in cash and cash equivalents	-640	-2,994	1,663
Cash and cash equivalents - Beginning of year	2,303	5,297	0
Cash and cash equivalents - End of year	$1,663	$2,303	$1,663

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (Deficiency) (USD $)

Total

Warrant [Member]

Settlement of Advances [Member]

Initial Public Offering [Member]

Series A Special Warrants [Member]

Rights [Member]

Oxiquant [Member]

Consultants [Member]

Financing Warrant [Member]

Financing Warrant [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Nonredeemable Preferred Stock [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Employees [Member]

Cadherin Biomedical Inc. [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Non-redeemable Preferred Stock of Subsidiary [Member]

Non-redeemable Preferred Stock of Subsidiary [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Other Comprehensive Income [Member]

Deficit Accumulated During Development Stage [Member]

Deficit Accumulated During Development Stage [Member]

Deficit Accumulated During Development Stage [Member]

In Thousands

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

February 2007 Financing [Member]

June 2004 Convertible Notes [Member]

December 2004 Convertible Notes [Member]

USD ($)

December 2004 Placement [Member]

May 2004 Placement [Member]

July 2005 Placement [Member]

May 2006 Placement [Member]

USD ($)

USD ($)

USD ($)

Warrant [Member]

Settlement of Advances [Member]

Initial Public Offering [Member]

Series A Special Warrants [Member]

Rights [Member]

Oxiquant [Member]

Financing Warrant [Member]

Financing Warrant [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Cadherin Biomedical Inc. [Member]

USD ($)

Nonredeemable Preferred Stock [Member]

USD ($)

Warrant [Member]

Series A Special Warrants [Member]

Rights [Member]

Oxiquant [Member]

Consultants [Member]

Financing Warrant [Member]

Financing Warrant [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Employees [Member]

USD ($)

USD ($)

Initial Public Offering [Member]

Rights [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

February 2007 Financing [Member]

April 2010 Financing [Member]

June 2004 Convertible Notes [Member]

December 2004 Convertible Notes [Member]

December 2004 Placement [Member]

May 2004 Placement [Member]

July 2005 Placement [Member]

May 2006 Placement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

February 2007 Financing [Member]

June 2004 Convertible Notes [Member]

December 2004 Convertible Notes [Member]

December 2004 Placement [Member]

May 2004 Placement [Member]

July 2005 Placement [Member]

May 2006 Placement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Beginning Balance at Sep. 02, 1996

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

'

'

Beginning Balance (in shares) at Sep. 02, 1996

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-37

'

'

Ending Balance at Jun. 30, 1997

-37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-37

'

'

Ending Balance (in shares) at Jun. 30, 1997

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-398

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-398

'

'

Ending Balance at Jun. 30, 1998

-435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-435

'

'

Beginning Balance (in shares) at Jun. 30, 1998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-89

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

239

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

1,615

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,615

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

Net (loss) income

-958

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-958

'

'

Ending Balance at Jun. 30, 1999

242

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,615

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

-1,393

'

'

Ending Balance (in shares) at Jun. 30, 1999

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

239

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants

'

255

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

255

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

793

'

175

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

793

'

175

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of equity rights

171

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

171

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cancellation of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

'

'

Net (loss) income

-1,605

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,605

'

'

Ending Balance at Jun. 30, 2000

47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,583

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

426

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36

-2,998

'

'

Ending Balance (in shares) at Jun. 30, 2000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

264

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants

'

1,722

'

'

4,335

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,722

4,335

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

341

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

341

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

5,689

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,727

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-38

'

Conversion of convertible securities (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

'

69

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,977

'

'

4,335

171

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,977

-4,335

-171

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

182

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

182

'

'

'

Net (loss) income

-2,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,524

'

'

Ending Balance at Jun. 30, 2001

9,792

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,134

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

218

-5,560

'

'

Ending Balance (in shares) at Jun. 30, 2001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

446

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11

'

'

'

Net (loss) income

-3,732

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,732

'

'

Ending Balance at Jun. 30, 2002

6,071

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,134

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

229

-9,292

'

'

Beginning Balance (in shares) at Jun. 30, 2002

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

446

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants

'

53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity component of convertible notes

1,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

446

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

'

11,620

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,077

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

543

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Distribution to shareholders

-158

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-158

'

'

Stated capital reduction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,489

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,489

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

-159

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-159

'

'

'

Net (loss) income

-17,795

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-17,795

'

'

Ending Balance at Jun. 30, 2003

698

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,726

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,147

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70

-27,245

'

'

Ending Balance (in shares) at Jun. 30, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

893

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repricing of warrants related to financing

18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of warrants

'

'

'

'

'

'

'

'

54

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

148

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity component of convertible notes

1,983

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,983

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

640

259

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

'

'

'

'

'

'

'

1,045

'

13,830

8,474

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,053

6,356

'

'

'

'

1,045

'

'

'

'

'

'

'

'

'

'

5,777

2,118

'

'

'

'

'

'

'

Conversion of convertible securities (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

96

60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible securities

'

'

'

'

'

'

'

'

'

'

1,123

171

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,216

569

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-93

-398

'

'

'

'

'

'

'

'

'

Exercise of stock options (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

23

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amalgamation of 2037357 Ontario Inc.

-22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

660

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,045

'

363

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amalgamation of 2037357 Ontario Inc., (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

-219

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-219

'

'

'

Net (loss) income

-6,872

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,872

'

'

Ending Balance at Jun. 30, 2004

20,454

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,603

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,117

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-149

-34,117

'

'

Ending Balance (in shares) at Jun. 30, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,993

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost related to SEC registration

-493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

39

'

'

'

'

'

'

'

'

'

'

604

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39

'

'

'

'

'

'

'

'

604

'

'

'

'

Stock Issued for Acquisitions (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued for Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,252

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,252

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative translation adjustment

1,392

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,392

'

'

'

Net (loss) income

-6,594

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,594

'

'

Ending Balance at Dec. 31, 2004

16,654

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,362

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,760

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-40,711

'

'

Ending Balance (in shares) at Dec. 31, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,030

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing costs

-141

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-141

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

276

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

276

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

337

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,134

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,060

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,074

'

'

'

'

'

'

Exercise of stock options (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-13,871

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13,871

'

'

Ending Balance at Dec. 31, 2005

11,077

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,306

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23,110

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-54,582

'

'

Ending Balance (in shares) at Dec. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,368

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

491

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

491

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

431

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,040

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,218

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

822

'

'

'

'

'

Net (loss) income

-16,440

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-16,440

'

'

Ending Balance at Dec. 31, 2006

1,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

46,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,523

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-71,022

'

'

Beginning Balance (in shares) at Dec. 31, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,799

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

116

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

563

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

131

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

59

'

'

'

'

'

'

'

'

'

'

2,263

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59

'

'

'

'

'

'

'

'

2,263

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,209

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

'

'

'

'

23,221

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,379

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-13,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13,357

'

'

Ending Balance at Dec. 31, 2007

14,148

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,355

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-84,379

'

'

Ending Balance (in shares) at Dec. 31, 2007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

88

'

'

'

'

'

'

'

'

'

'

2,417

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

88

'

'

'

'

'

'

'

'

2,417

'

'

'

'

Net (loss) income

-13,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-13,600

'

'

Ending Balance at Dec. 31, 2008

3,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-97,979

'

'

Ending Balance (in shares) at Dec. 31, 2008

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

355

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

355

'

'

'

'

Net (loss) income

-3,012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,012

'

'

Ending Balance at Dec. 31, 2009

406

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,225

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-100,991

'

'

Ending Balance (in shares) at Dec. 31, 2009

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

53

'

'

'

'

'

'

'

'

'

'

2,439

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53

'

'

'

'

'

'

'

'

2,439

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,337

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-7,823

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7,823

'

'

Ending Balance at Dec. 31, 2010

-4,925

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,717

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-108,814

'

'

Ending Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,461

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

129

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

'

'

'

'

129

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,697

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

-28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,023

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

199

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,250

Net (loss) income

4,685

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,685

'

'

Ending Balance at Dec. 31, 2011

-119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,952

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,065

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-105,379

'

'

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,158

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

152

'

'

'

'

'

'

'

'

'

'

174

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152

'

'

'

'

'

'

'

'

174

'

'

'

'

Net (loss) income

-5,163

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,163

'

'

Ending Balance at Dec. 31, 2012

-4,957

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,952

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,391

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,243

-110,543

'

'

Ending Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,158

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options issued

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

62

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

1,570

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

838

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

732

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

1,845

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,845

'

'

Ending Balance at Dec. 31, 2013

($1,455)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$66,790

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$39,210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,243

($108,698)

'

'

Ending Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,158

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Going_Concern

Going Concern	12 Months Ended
	Dec. 31, 2013
Going Concern [Abstract]	'
Going Concern	'
	1.         Going Concern
	Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive.
	These consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.
	The Company is a development stage company and during the year ended December 31, 2013, incurred a loss from operations of $1,931. At December 31, 2013, it had an accumulated deficit of $108,698, and had experienced negative cash flows from operating activities since inception in the amount of $87,247. In addition, it had a deficiency in working capital at December 31, 2013 and the Company's operating losses since inception.
	These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance our business strategy, operations and growth through the issuance of equity, debt or collaboration. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing.
	These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2.         Significant Accounting Policies
	Basis of presentation
	The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.
	On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.
	The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2013, the Company had $1,663 in cash accounts (2012- $2,303). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments.
	Financial instruments
	Financial instruments recognized on the balance sheets at December 31, 2013 and December 31, 2012 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative liabilities, the carrying values of which, with the exception of the derivative liabilities, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value.
	The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.
	The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.
	Common stock and warrants
	At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency.
	In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40.  In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. The Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this resulted in warrants being shown as a liability which is marked to market as at December 31, 2013 and December 31, 2012. At December 31, 2013, the derivative liabilities were valued at $2,863 (2012: $6,640) and the unrealized gain on the value of the underlying securities was $3,777 (2012: loss $1,563) for the year ended December 31, 2013.
	Revenue recognition
	At this time, the Company does not have any revenue.
	Research and development costs and investment tax credits
	Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.
	Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.
	Income taxes
	The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.
	Foreign currency translation
	The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.
	Earnings/(Loss) per share
	Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the if-converted method and treasury methods. Accordingly, options to purchase 5,319 and warrants to purchase 21,665 shares at December 31, 2013, were not included in earnings per share. These options and warrant were not included in the computation of diluted earnings per share because the exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect. In 2012 we incurred a net loss and accordingly none of the options or warrants outstanding, 5,498 and 18,385, respectively, were included in loss per share because their effect would be antidilutive.
	Newly adopted accounting pronouncements
	In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company was required to adopt this ASU in the first quarter for fiscal 2013. The adoption of this standard did not have a significant impact on the Company’s reporting.
	Recent accounting pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," an amendment to FASB Accounting Standards Codification, or "ASC" Topic 740, Income Taxes, or "FASB ASC Topic 740." This update clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted. This accounting guidance is not expected to have a material impact on our consolidated financial statements or financial statement disclosures.

Stock_options

Stock options	12 Months Ended
	Dec. 31, 2013
Stock Options Abstract	'
Stock options	'
	3.        Stock options
	The Compensation Committee of the Board of Directors administers the Company’s stock option plan.  The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time. Based upon the current shares outstanding, a maximum of 7,290 options are authorized for issuance under the plan.  The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant.  The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2013 is below.
	The following options granted under the stock option plan are exercisable in Canadian dollars:
							Exercise Price in Canadian
							Dollars
				Number of			Range			Weighted-
				Options						average
	Outstanding at December 31, 2011			4,171				0.54-0.81		$	0.78
	Granted			-				-			-
	Exercised			-				-			-
	Forfeited or expired			-				-			-
	Outstanding at December 31, 2012			4,171				0.54-0.81			0.78
	Granted			-				-			-
	Exercised			-				-			-
	Forfeited or expired			-78				0.81			0.81
	Outstanding at December 31, 2013			4,093			$	0.54-0.81		$	0.79
	Price in Canadian Dollars			# outstanding and			Weighted average remaining life (years)
				exercisable at
				December 31, 2013
	$	0.54			88			4.26
	$	0.63			303			4.21
	$	0.81			3,702			3.97
	TOTAL				4,093			3.99
	The following options granted under the stock option plan are exercisable in U.S. dollars:
						Exercise Price in U.S. Dollars
				Number of		Range				Weighted-
				Options						average
	Outstanding at December 31, 2011			963		$	0.50 - 24.30		$	8.51
	Granted			1,137			0.15 - 0.56			0.32
	Exercised			-			-			-
	Forfeited or expired			-773			5.04 – 24.30			9.92
	Outstanding at December 31, 2012			1,327			0.15 - 11.34			0.67
	Granted			315			0.24 - 0.98			0.32
	Exercised			-			-			-
	Forfeited or expired			-11			5.22 - 10.26			10.14
	Outstanding at December 31, 2013			1,631		$	0.15-10.26		$	0.6
	Price in US Dollars			# Outstanding and			Remaining life
				Exercisable at			(years)
				December 31, 2013
	$	0.15			33			5.71
	$	0.18			61			5.45
	$	0.2			254			5.33
	$	0.24			250			6.74
	$	0.32			31			6.71
	$	0.35			689			5.97
	$	0.5			94			4.95
	$	0.56			100			6.05
	$	0.63			44			4.7
	$	0.8			25			6.35
	$	0.98			10			6.47
	$	1.8			4			1.73
	$	5.04			7			0.23
	$	5.22			2			1.42
	$	7.2			2			0.71
	$	10.26			12			0.38
	$	11.34			13			0.13
					1,631			5.73
	Stock compensation expense for the fiscal years ended December 31, 2013 and 2012 was $87 and $326 respectively.  These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2013 and 2012 was $0.32 and $0.32, respectively. The intrinsic value (being the difference between the share price as at December 31, 2013 and exercise price) of stock options outstanding at December 31, 2013 was NIL.
	The fair values of options granted in fiscal years ended December 31, 2013 and 2012 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:
			Year Ended			Year Ended
			December 31,			December 31,
			2013			2012
	Expected dividend		0	%		0	%
Risk-free interest rate		1.10-1.73	%		1.09–1.26	%
Expected volatility		144-175	%		118-133	%
Expected life		7 years			7 years
The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2013
Derivative Instruments [Abstract]	'
Derivative Instruments	'
	4.      Derivative Liabilities
	Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency.
	The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:
		·	Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and
		·	Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016.
	These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model.
	As of December 31, 2013, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $2,015 and $794 respectively (December 31, 2012 – warrants expiring April 30, 2015, fair value of $4,698, March 29, 2016, fair value of $1,847), and the gain on these warrants for the twelve months ended December 31, 2013 was $2,683 and $1,052, respectively (December 31, 2012 - warrants expiring April 30, 2015, loss of $1,026; March 29, 2016, gain of $507). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.
	Gain/(Loss) on Derivative Instruments		Twelve months ended December 31, 2013		Twelve months ended December 31, 2012
	Warrant expiring April 15, 2015			2,683		-1,026
	Warrant expiring March 29, 2016			1,052		-507
	Rights offering derivative			-		-
	Options to contractors			42		-30
	Total			3,777		-1,563
	During the fiscal year ended December 31, 2011, the Company issued 108 options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718):Effect of Denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. The fair value of these options at December 31, 2013 and December 31, 2012 was $54 and $96 respectively. The gain for the twelve months ended December 31, 2013 and December 31, 2012 was $42 and a loss of $30 respectively.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	5.         Fair Value Measurements
	The Company has adopted Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	Assets/Liabilities Measured at Fair Value on a Recurring Basis
	Fair Value Measurement at December 31, 2013
		Quoted Price in Active Markets		Significant Other		Significant
		for Identical Instruments		Observable Inputs		Unobservable Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	-	$	1,663	$	-	$	1,663
	Liabilities
	Derivative liabilities		-		2,863		-		2,863
	The Company's financial instruments include cash equivalents and derivative liabilities. Only cash equivalents and derivative liabilities are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions; expected dividend 0%; risk-free interest rate of 1.10%-1.73%; expected volatility of 144% - 175%; and a 1.3 or 2.2 year remaining life. The options also use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.43%-1.46% expected volatility of 154%- 172%; and a 3.9-4.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Shareholders' Equity	'
	6.         Shareholders’ Equity
	Authorized capital stock
	The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.
	On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “share consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the share shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our 2011 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).
	Equity financings
	On November 22, 2013, the Company completed the closing of non-brokered private placement (the “Offering”) of 4,000 units for gross proceeds of US$1,600.  Each unit (a “Unit”) was issued at a price of $0.40 per Unit and consisted of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”). Each Warrant entitles the holder thereof to acquire one Common Share at a price of US$0.50 per share for a period of five years from the date of issuance.
	Warrants to Purchase Common Stock
	At December 31, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years. The Company also had warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $0.50 and a weighted average remaining life of 6.9 years:
	Warrant Description	Common Shares Issuable Upon
		Exercise of Outstanding
	(Warrants in thousands)	Warrants at December 31, 2013		Exercise Price CND/USD		Expiration Date
	Investor Warrants (1)		13,337	$	1.44 CND	30-Apr-15
	Investor Warrants (2)		4,698	$	1.44 CND	29-Mar-16
	Investor Warrants (3)		4,000	$	0.50 USD	22-Nov-20
			22,035
	(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
	(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

Research_and_Development

Research and Development	12 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]	'
Research and Development	'
	7.         Research and Development
	Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:
		Year Ended		Year Ended		Cumulative From
		December 31,		December 31,		September 3, 1996 to
						December 31,
		2013		2012		2013
	Research and development	$	579	$	2,075	$	69,746
	Investment tax credits		-		-		-1,632
	National Research Council grants		-		-		-197
		$	579	$	2,075	$	67,917

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments [Abstract]	'
Commitments and Contingencies	'
	8.      Commitments and Contingencies
	LifeSci Advisors, LLC.
	The Company has a service agreement with LifeSci Advisors, LLC under which it is required to make several payments over the course of the agreement. LifeSci Advisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.
		Less than		3-Jan		Total
		1 year		years
	LifeSci Advisors, LLC		55		-		55
	Total	$	55	$	-	$	55
	Oregon Health & Science University Agreement
	On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, a 2.5 percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5 percent royalty on any consideration received from sublicensing of the licensed technology. Milestone payment fees payable to OHSU include $100,000 upon first commercial sale for any licensed product.
	On February 20, 2013, Adherex terminated the previous exclusive license agreement with OHSU and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002 (the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, OHSU was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007.
	The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Adherex, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Adherex or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	Exercise of Stock Options
	On March 5, 2014, Dr. Tom Spector exercised 150,000 options which were granted to him on November 20, 2012 pursuant to the Company's Amended and Restated Stock Option Plan at an aggregate exercise price of $52,500 or $0.35 per common share. On June 19, 2013 Dr. Spector resigned as Chief Scientific Officer of the Company.
	Non-Executive Compensation
	On January 24, 2014, the board approved an increase in non-executive compensation from $1,500 per meeting attended to $2,000 per meeting attended for both Chris Rallis and Steven Skolsky. There was no change to the non-cash compensation for Mr. Rallis or Mr. Skolsky.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	10.      Income Taxes
	The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:
		Year Ended				Year Ended
		December 31,				December 31,
		2013				2012
	Domestic gain		2,620				-4,397
	Foreign loss		-775				-766
	Gain before income taxes		1,845				-5,163
	Expected statutory rate (recovery)		26.5	%			26.5	%
	Expected provision for (recovery of) income tax		489				-1,368
	Permanent differences		-977				489
	Change in valuation allowance		230				2,467
	Non-refundable investment tax credits		-				-
	Effect of foreign exchange rate differences		36				-245
	Effect of change in future enacted tax rates		-				-1,378
	Effect of tax rate changes and other		222				36
	Provision for income taxes	$	-			$	-
	The Canadian statutory come tax rate of 26.5 percent is comprised of federal income tax at approximately 15.5 percent and provincial income tax at approximately 11.0 percent.
	The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2013, December 31, 2012:
		December 31,			December 31,
		2013			2012
	Future tax assets:
	SR&ED expenditures		2,195			2,195
	Income tax loss carryforwards		22,220			21,783
	Non-refundable investment tax credits		1,719			1,719
	Share issue costs		31			25
	Accrued expenses		-			-
	Fixed and intangible assets		1,006			970
	Harmonization credit		-			248
			27,170			26,940
	Less: valuation allowance		-27,170			-26,940
	Net future tax assets	$	-		$	-
	There are no current income taxes owed, nor are any income taxes expected to be owed in the near term.
	At December 31, 2013 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry forwards and non-refundable investment tax credits.  The unclaimed amounts and their expiry dates are as listed below:
		Federal			Province/
					State
	SR&ED expenditures (no expiry)	$	8,283		$	-
	Income tax loss carryforwards (expiry date):
	2014		6,089			6,089
	2015		11,499			11,499
	2021		26			-
	2022		233			-
	2023		133			-
	2024		1,536			1,455
	2025		4,795			4,768
	2026		20,562			20,496
	2027		8,340			8,320
	2028		10,840			10,823
	2029		8,502			8,502
	2030		2,608			2,607
	2031		3,377			3,377
	2032		3,491			3,491
	2033		1,817			1,817
	Investment tax credits (expiry date):
	2018		10
	2019		8
	2020		96
	2021		55
	2022		548
	2023		399
	2024		178
	2025		199
	2026		86
2027		90
2028		50

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation
	The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation.
	On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding).
Use of estimates	'
	Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation. Actual results could differ from those estimates.
Cash and cash equivalents	'
	Cash and Cash Equivalents
	Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less.
	The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2013, the Company had $1,663 in cash accounts (2012- $2,303). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments.
Financial instruments	'
	Financial instruments
	Financial instruments recognized on the balance sheets at December 31, 2013 and December 31, 2012 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative liabilities, the carrying values of which, with the exception of the derivative liabilities, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value.
	The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper.
	The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature.
Common stock and warrants	'
	Common stock and warrants
	At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency.
	In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40.  In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. The Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this resulted in warrants being shown as a liability which is marked to market as at December 31, 2013 and December 31, 2012. At December 31, 2013, the derivative liabilities were valued at $2,863 (2012: $6,640) and the unrealized gain on the value of the underlying securities was $3,777 (2012: loss $1,563) for the year ended December 31, 2013.
Revenue recognition	'
	Revenue recognition
	At this time, the Company does not have any revenue.
Research and development costs and investment tax credits	'
	Research and development costs and investment tax credits
	Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred.
	Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized.
Income taxes	'
	Income taxes
	The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense.
Foreign currency translation	'
	Foreign currency translation
	The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations.
Earnings/(Loss) per share	'
	Earnings/(Loss) per share
	Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the if-converted method and treasury methods. Accordingly, options to purchase 5,319 and warrants to purchase 21,665 shares at December 31, 2013, were not included in earnings per share. These options and warrant were not included in the computation of diluted earnings per share because the exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect. In 2012 we incurred a net loss and accordingly none of the options or warrants outstanding, 5,498 and 18,385, respectively, were included in loss per share because their effect would be antidilutive.
Newly adopted accounting pronouncements	'
	Newly adopted accounting pronouncements
	In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company was required to adopt this ASU in the first quarter for fiscal 2013. The adoption of this standard did not have a significant impact on the Company’s reporting.
Recent accounting pronouncements	'
	Recent accounting pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," an amendment to FASB Accounting Standards Codification, or "ASC" Topic 740, Income Taxes, or "FASB ASC Topic 740." This update clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted. This accounting guidance is not expected to have a material impact on our consolidated financial statements or financial statement disclosures.

Stock_options_Tables

Stock options (Tables)	12 Months Ended
	Dec. 31, 2013
Fair values of options granted using weighted average assumptions	'
	The fair values of options granted in fiscal years ended December 31, 2013 and 2012 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions:
			Year Ended			Year Ended
			December 31,			December 31,
			2013			2012
	Expected dividend		0	%		0	%
	Risk-free interest rate		1.10-1.73	%		1.09–1.26	%
	Expected volatility		144-175	%		118-133	%
	Expected life		7 years			7 years
Currency, Canadian Dollar [Member]	'
Options granted under the stock option plan are exercisable	'
	The following options granted under the stock option plan are exercisable in Canadian dollars:
							Exercise Price in Canadian
							Dollars
				Number of			Range			Weighted-
				Options						average
	Outstanding at December 31, 2011			4,171				0.54-0.81		$	0.78
	Granted			-				-			-
	Exercised			-				-			-
	Forfeited or expired			-				-			-
	Outstanding at December 31, 2012			4,171				0.54-0.81			0.78
	Granted			-				-			-
	Exercised			-				-			-
	Forfeited or expired			-78				0.81			0.81
	Outstanding at December 31, 2013			4,093			$	0.54-0.81		$	0.79
Options reinstated agreement either expired and cancelled prior to the agreed severance	'
	Price in Canadian Dollars			# outstanding and			Weighted average remaining life (years)
				exercisable at
				December 31, 2013
	$	0.54			88			4.26
	$	0.63			303			4.21
	$	0.81			3,702			3.97
	TOTAL				4,093			3.99
Currency, U.S. Dollar [Member]	'
Options granted under the stock option plan are exercisable	'
	The following options granted under the stock option plan are exercisable in U.S. dollars:
						Exercise Price in U.S. Dollars
				Number of		Range				Weighted-
				Options						average
	Outstanding at December 31, 2011			963		$	0.50 - 24.30		$	8.51
	Granted			1,137			0.15 - 0.56			0.32
	Exercised			-			-			-
	Forfeited or expired			-773			5.04 – 24.30			9.92
	Outstanding at December 31, 2012			1,327			0.15 - 11.34			0.67
	Granted			315			0.24 - 0.98			0.32
	Exercised			-			-			-
	Forfeited or expired			-11			5.22 - 10.26			10.14
	Outstanding at December 31, 2013			1,631		$	0.15-10.26		$	0.6
Options reinstated agreement either expired and cancelled prior to the agreed severance	'
	Price in US Dollars			# Outstanding and			Remaining life
				Exercisable at			(years)
				December 31, 2013
	$	0.15			33			5.71
	$	0.18			61			5.45
	$	0.2			254			5.33
	$	0.24			250			6.74
	$	0.32			31			6.71
	$	0.35			689			5.97
	$	0.5			94			4.95
	$	0.56			100			6.05
	$	0.63			44			4.7
	$	0.8			25			6.35
	$	0.98			10			6.47
	$	1.8			4			1.73
	$	5.04			7			0.23
	$	5.22			2			1.42
	$	7.2			2			0.71
	$	10.26			12			0.38
	$	11.34			13			0.13
					1,631			5.73

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments [Abstract]	'
Gain Loss on Derivative Instruments	'
	Gain/(Loss) on Derivative Instruments	Twelve months ended December 31, 2013		Twelve months ended December 31, 2012
	Warrant expiring April 15, 2015		2,683		-1,026
	Warrant expiring March 29, 2016		1,052		-507
	Rights offering derivative		-		-
	Options to contractors		42		-30
	Total		3,777		-1,563

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assets/Liabilities Measured at Fair Value on Recurring Basis	'
	Assets/Liabilities Measured at Fair Value on a Recurring Basis
	Fair Value Measurement at December 31, 2013
		Quoted Price in Active Markets		Significant Other		Significant
		for Identical Instruments		Observable Inputs		Unobservable Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	-	$	1,663	$	-	$	1,663
	Liabilities
	Derivative liabilities		-		2,863		-		2,863

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Warrants Outstanding to Purchase Common Stock	'
	At December 31, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years. The Company also had warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $0.50 and a weighted average remaining life of 6.9 years:
	Warrant Description	Common Shares Issuable Upon
		Exercise of Outstanding
	(Warrants in thousands)	Warrants at December 31, 2013		Exercise Price CND/USD		Expiration Date
	Investor Warrants (1)		13,337	$	1.44 CND	30-Apr-15
	Investor Warrants (2)		4,698	$	1.44 CND	29-Mar-16
	Investor Warrants (3)		4,000	$	0.50 USD	22-Nov-20
			22,035
	(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
	(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

Research_and_Development_Table

Research and Development (Tables)	12 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]	'
Research and Development	'
	Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows:
		Year Ended		Year Ended		Cumulative From
		December 31,		December 31,		September 3, 1996 to
						December 31,
		2013		2012		2013
	Research and development	$	579	$	2,075	$	69,746
	Investment tax credits		-		-		-1,632
	National Research Council grants		-		-		-197
		$	579	$	2,075	$	67,917

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments [Abstract]	'
Commitments and Contingencies	'
	The Company has a service agreement with LifeSci Advisors, LLC under which it is required to make several payments over the course of the agreement. LifeSci Advisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform.
		Less than		3-Jan		Total
		1 year		years
	LifeSci Advisors, LLC		55		-		55
	Total	$	55	$	-	$	55

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Reconciliation of the combined income tax rate	'
	A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows:
		Year Ended				Year Ended
		December 31,				December 31,
		2013				2012
	Domestic gain		2,620				-4,397
	Foreign loss		-775				-766
	Gain before income taxes		1,845				-5,163
	Expected statutory rate (recovery)		26.5	%			26.5	%
	Expected provision for (recovery of) income tax		489				-1,368
	Permanent differences		-977				489
	Change in valuation allowance		230				2,467
	Non-refundable investment tax credits		-				-
	Effect of foreign exchange rate differences		36				-245
	Effect of change in future enacted tax rates		-				-1,378
	Effect of tax rate changes and other		222				36
	Provision for income taxes	$	-			$	-
Summary Of Tax Credit Carryforwards	'
	The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2013, December 31, 2012:
		December 31,			December 31,
		2013			2012
	Future tax assets:
	SR&ED expenditures		2,195			2,195
	Income tax loss carryforwards		22,220			21,783
	Non-refundable investment tax credits		1,719			1,719
	Share issue costs		31			25
	Accrued expenses		-			-
	Fixed and intangible assets		1,006			970
	Harmonization credit		-			248
			27,170			26,940
	Less: valuation allowance		-27,170			-26,940
	Net future tax assets	$	-		$	-
	The unclaimed amounts and their expiry dates are as listed below:
		Federal			Province/
					State
	SR&ED expenditures (no expiry)	$	8,283		$	-
	Income tax loss carryforwards (expiry date):
	2014		6,089			6,089
	2015		11,499			11,499
	2021		26			-
	2022		233			-
	2023		133			-
	2024		1,536			1,455
	2025		4,795			4,768
	2026		20,562			20,496
	2027		8,340			8,320
	2028		10,840			10,823
	2029		8,502			8,502
	2030		2,608			2,607
	2031		3,377			3,377
	2032		3,491			3,491
	2033		1,817			1,817
	Investment tax credits (expiry date):
	2018		10
	2019		8
	2020		96
	2021		55
	2022		548
	2023		399
	2024		178
	2025		199
	2026		86
	2027		90
	2028		50

Going_Concern_Additional_Infor

Going Concern - Additional Information (Details) (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Going Concern [Line Items]	'	'	'
Loss from operations	($1,931)	($3,620)	($116,176)
Net cash used in operating activities	2,210	2,994	87,247
Deficit accumulated during development stage	$108,698	$110,543	$108,698

Significant_Accounting_Policie2

Significant Accounting Policies - Additional Information (Details) (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Sep. 02, 1996
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Cash and cash equivalents - Beginning of period	$1,663	$2,303	$1,663	$5,297	$0
Derivative liability	2,863	6,640	2,863	'	'
Gain/(loss) on derivative warrants	$3,777	($1,563)	$7,034	'	'
Warrant [Member]	'	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,665	18,385	'	'	'
Stock Option [Member]	'	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,319	5,498	'	'	'

Stock_Options_Options_Granted_

Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details)

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Stock Option In Canadian Dollars [Member]

Stock Option In Canadian Dollars [Member]

Stock Option In Us Dollars [Member]

Stock Option In Us Dollars [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

CAD

CAD

USD ($)

USD ($)

Stock Option In Canadian Dollars [Member]

Stock Option In Canadian Dollars [Member]

Stock Option In Us Dollars [Member]

Stock Option In Us Dollars [Member]

Stock Option In Canadian Dollars [Member]

Stock Option In Canadian Dollars [Member]

Stock Option In Us Dollars [Member]

Stock Option In Us Dollars [Member]

CAD

CAD

USD ($)

USD ($)

CAD

CAD

USD ($)

USD ($)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Number of Options

4,171

4,171

1,327

963

'

'

'

'

'

'

'

'

Granted Number of Options

0

0

315

1,137

'

'

'

'

'

'

'

'

Exercised Number of Options

0

0

0

0

'

'

'

'

'

'

'

'

Forfeited or expired Number of Options

-78

0

-11

-773

'

'

'

'

'

'

'

'

Outstanding Number of Options

4,093

4,171

1,631

1,327

'

'

'

'

'

'

'

'

Outstanding Range

'

'

'

'

0.54

0.54

$0.15

$0.50

0.81

0.81

$11.34

$24.30

Granted Range

0

0

'

'

'

'

$0.24

$0.15

'

'

$0.98

$0.56

Exercised Range

0

0

$0

$0

'

'

$0.24

'

'

'

$0.98

'

Forfeited or expired Range

0.81

0

'

'

'

'

$5.22

$5.04

'

'

$10.26

$24.30

Outstanding Range

'

'

'

'

0.54

0.54

$0.15

$0.15

0.81

0.81

$10.26

$11.34

Outstanding Weighted- average

0.78

0.78

$0.67

$8.51

'

'

'

'

'

'

'

'

Granted Weighted- average

0

0

$0.32

$0.32

'

'

'

'

'

'

'

'

Exercised Weighted- average

0

0

$0

$0

'

'

'

'

'

'

'

'

Forfeited or expired Weighted- average

0.81

0

$10.14

$9.92

'

'

'

'

'

'

'

'

Outstanding Weighted- average

0.79

0.78

$0.60

$0.67

'

'

'

'

'

'

'

'

Stock_options_Price_In_Canadia

Stock options (Price In Canadian Dollars) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average remaining life (years)	'5 years 8 months 23 days
Price In Canadian Dollars 0.54 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and exercisable	88
Weighted average remaining life (years)	'4 years 3 months 4 days
Price In Canadian Dollars 0.63 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and exercisable	303
Weighted average remaining life (years)	'4 years 2 months 16 days
Price In Canadian Dollars 0.81 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and exercisable	3,702
Weighted average remaining life (years)	'3 years 11 months 19 days
Currency Canadian Dollar [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and exercisable	4,093
Weighted average remaining life (years)	'3 years 11 months 26 days

Stock_Options_Price_In_US_Doll

Stock Options (Price In US Dollars) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	1,631
Remaining life (years)	'5 years 8 months 23 days
Price In Us Dollars 0.15 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	33
Remaining life (years)	'5 years 8 months 16 days
Price In Us Dollars 0.18 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	61
Remaining life (years)	'5 years 5 months 12 days
Price In Us Dollars 0.20 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	254
Remaining life (years)	'5 years 3 months 29 days
Price In Us Dollars 0.24 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	250
Remaining life (years)	'6 years 8 months 26 days
Price In Us Dollars 0.32 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	31
Remaining life (years)	'6 years 8 months 16 days
Price In Us Dollars 0.35 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	689
Remaining life (years)	'5 years 11 months 19 days
Price In Us Dollars 0.50 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	94
Remaining life (years)	'4 years 11 months 12 days
Price In Us Dollars 0.56 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	100
Remaining life (years)	'6 years 18 days
Price In Us Dollars 0.63 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	44
Remaining life (years)	'4 years 8 months 12 days
Price In US Dollars 0.80 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	25
Remaining life (years)	'6 years 4 months 6 days
Price In Us Dollars 0.98 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	10
Remaining life (years)	'6 years 5 months 19 days
Price In Us Dollars 1.80 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	4
Remaining life (years)	'1 year 8 months 23 days
Price In Us Dollars 5.04 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	7
Remaining life (years)	'2 months 23 days
Price In Us Dollars 5.22 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	2
Remaining life (years)	'1 year 5 months 1 day
Price In Us Dollars 7.20 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	2
Remaining life (years)	'8 months 16 days
Price In Us Dollars 10.26 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	12
Remaining life (years)	'4 months 17 days
Price In Us Dollars 11.34 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding and Exercisable	13
Remaining life (years)	'1 month 17 days

Stock_options_Options_Were_Gra

Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected dividend	0.00%	0.00%
Expected life	'7 years	'7 years
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	1.10%	1.09%
Expected volatility	144.00%	118.00%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	1.73%	1.26%
Expected volatility	175.00%	133.00%

Stock_options_Additional_Infor

Stock options - Additional Information (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 24, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2010	Jun. 24, 2010
		General and Administrative Expense [Member]	General and Administrative Expense [Member]	Stock Option [Member]	Stock Option [Member]	Stock Option [Member]	Plan Maximum Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Shares issuable under Stock Option Plan	'	'	'	'	'	20,000	7,290
Percentage Of Total Number Of Share Issued and Outstanding	25.00%	'	'	'	'	'	'
Allocated Share-based Compensation Expense	'	$87	$326	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	$0.32	$0.32	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	'	'	'	$0	'	'	'

Derivative_Liabilities_Gain_Lo

Derivative Liabilities (Gain Loss on Derivative Instruments) (Details) (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain/(Loss) on Derivative Instruments	$3,777	($1,563)	$7,034
Warrant expiring April 15, 2015 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain/(Loss) on Derivative Instruments	2,683	-1,026	'
Warrant expiring March 29, 2016 [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain/(Loss) on Derivative Instruments	1,052	-507	'
Rights Offering Derivative [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain/(Loss) on Derivative Instruments	0	0	'
Options to Contractors [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain/(Loss) on Derivative Instruments	$42	($30)	'

Derivative_Liabilities_Additio

Derivative Liabilities - Additional Information (Details)

12 Months Ended

208 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

USD ($)

USD ($)

USD ($)

Options Held [Member]

Options Held [Member]

Investor warrants expiring April 30, 2015 [Member]

Investor warrants expiring April 30, 2015 [Member]

Investor warrants expiring April 30, 2015 [Member]

Investor warrants expiring March 29, 2016 [Member]

Investor warrants expiring March 29, 2016 [Member]

Investor warrants expiring March 29, 2016 [Member]

Rights Offering Derivative [Member]

Rights Offering Derivative [Member]

Options to Contractors [Member]

Options to Contractors [Member]

Options to Contractors [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issuable upon exercise of outstanding warrants

22,035

'

22,035

'

'

13,337

[1]

'

'

4,698

[2]

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

1.44

[1]

'

'

1.44

[2]

'

'

'

'

'

Expiration Date

'

'

'

'

'

30-Apr-15

[1]

'

'

29-Mar-16

[2]

'

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

$2,015

$4,698

'

$794

$1,847

'

'

'

'

'

'

Gain/(Loss) on Derivative Instruments

3,777

-1,563

7,034

'

'

2,683

-1,026

'

1,052

-507

'

0

0

42

-30

'

Rights offered for each common shares held

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

108

Derivative Liability

'

'

'

$54

$96

'

'

'

'

'

'

'

'

'

'

'

[1]

On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (bPrivate Placementb) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

[2]

On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) (Fair Value, Measurements, Recurring, USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Cash equivalents	$1,663
Derivative liabilities	2,863
Quoted Price in Active Markets for Identical Instruments Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Cash equivalents	0
Derivative liabilities	0
Significant Other Observable Inputs Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Cash equivalents	1,663
Derivative liabilities	2,863
Significant Unobservable Inputs Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'
Cash equivalents	0
Derivative liabilities	$0

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2013
Warrant [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Expected dividend rate	0.00%
Warrant [Member] | Minimum [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Risk free interest rate	1.10%
Expected volatility rate	144.00%
Expected life	'1 year 3 months 18 days
Warrant [Member] | Maximum [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Risk free interest rate	1.73%
Expected volatility rate	175.00%
Expected life	'2 years 2 months 12 days
Employee Stock Option [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Expected dividend rate	0.00%
Employee Stock Option [Member] | Minimum [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Risk free interest rate	1.43%
Expected volatility rate	154.00%
Expected life	'3 years 10 months 24 days
Employee Stock Option [Member] | Maximum [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Risk free interest rate	1.46%
Expected volatility rate	172.00%
Expected life	'4 years 4 months 24 days

Shareholders_Equity_Warrants_O

Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details)	Dec. 31, 2013	Dec. 31, 2013		Dec. 31, 2013		Dec. 31, 2013
In Thousands, unless otherwise specified		Investor warrants expiring April 30, 2015 [Member]		Investor warrants expiring March 29, 2016 [Member]		Investor Warrants expiring Novermber 22, 2020 [Member]
Class of Warrant or Right [Line Items]	'	'		'		'
Common Shares Issuable Upon Exercise of Outstanding Warrants at December 31, 2013	22,035	13,337	[1]	4,698	[2]	4,000
Exercise Price CND/USD	'	1.44	[1]	1.44	[2]	0.5
Expiration Date	'	30-Apr-15	[1]	29-Mar-16	[2]	22-Nov-20
[1]	On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (bPrivate Placementb) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.
[2]	On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date.

Shareholders_Equity_Warrants_O1

Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details)	Dec. 31, 2013	Apr. 30, 2010	Mar. 29, 2011	Mar. 29, 2011
In Thousands, except Per Share data, unless otherwise specified		Private Placement [Member]	Non-Broker Rights Offering [Member]	Non-Broker Rights Offering [Member]
		CAD	USD ($)	CAD
Class of Warrant or Right [Line Items]	'	'	'	'
Issuance of stock, price per share	'	0.03	'	0.03
Proceeds from issuance of unit	'	7,200	$2,547	'
Common shares issuable upon exercise of outstanding warrants	22,035	18	18	18
Warrants, exercise Price	'	1.44	1.44	1.44
Stock Issued During Period, Shares, New Issues	'	240,066	84,559	84,559

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Details)	12 Months Ended		208 Months Ended			1 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Nov. 22, 2013	Nov. 22, 2013
	USD ($)	USD ($)	USD ($)	U.S.dollars [Member]	Canadian dollars [Member]	Private Placement [Member]	Gross Proceeds [Member]
						Equity Financing [Member]	Private Placement [Member]
						USD ($)	Equity Financing [Member]
							USD ($)
Stockholders Equity Note [Line Items]	'	'	'	'	'	'	'
Weighted average exercise price of warrants	'	'	'	0.5	1.44	'	'
Weighted average remaining life of warrants	'	'	'	'6 years 10 months 24 days	'2 years 7 months 6 days	'	'
Share Price	'	'	'	'	'	'	$4,000
Issuance of units, net of issue costs	$1,570	$0	$88,013	'	'	'	$1,600
Price Per Units	'	'	'	'	'	$0.40	'

Research_and_Development_Inves

Research and Development (Investment Tax Credits Earned) (Details) (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'
Research and development	$579	$2,075	$69,746
Investment tax credits	0	0	-1,632
National Research Council grants	0	0	-197
Research and Development Net	$579	$2,075	$67,917

Commitments_and_Contingencies_1

Commitments and Contingencies (Contractual Obligations and Commitments) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Loss Contingencies [Line Items]	'
Less than 1 year	$55
1-3 years	0
Total	55
LifeSci Advisors, LLC [Member]	'
Loss Contingencies [Line Items]	'
Less than 1 year	55
1-3 years	0
Total	$55

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Details) (USD $)	1 Months Ended
In Thousands, unless otherwise specified	Feb. 20, 2013
Loss Contingencies [Line Items]	'
Milestone Payment Fees	$100,000
Issue Of Convertible Common Stock As Per Licence Agreement	13,902
Expired Convertible Common Stock	21,250
Licensed Product [Member]	'
Loss Contingencies [Line Items]	'
Royalty Percent	2.50%
Discount On Royalty Percent	1.00%
Minimum Amount To Be Bought To Get Discount On Royalty	$150,000
Sublicensed Technology [Member]	'
Loss Contingencies [Line Items]	'
Royalty Percent	5.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (USD $)	12 Months Ended		208 Months Ended	1 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 05, 2014	Jan. 24, 2014
				Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	'	'	'	150,000	'
Proceeds From Stock Options Exercised	$0	$0	$51	$52,500	'
Non Executive Compensation	'	'	'	'	1,500
Increase Decrease In Non Executive Compensation	'	'	'	'	$2,000
Exercise price per common share	'	'	'	$0.35	'

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Effective Tax Rate [Line Items]	'	'
Domestic gain	$2,620	($4,397)
Foreign loss	-775	-766
Gain before income taxes	1,845	-5,163
Expected statutory rate (recovery)	26.50%	26.50%
Expected provision for (recovery of) income tax	489	-1,368
Permanent differences	-977	489
Change in valuation allowance	230	2,467
Non-refundable investment tax credits	0	0
Effect of foreign exchange rate differences	36	-245
Effect of change in future enacted tax rates	0	-1,378
Effect of tax rate changes and other	222	36
Provision for income taxes	$0	$0

Income_Taxes_Future_Income_Tax

Income Taxes (Future Income Taxes (Recovery)) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	$27,170	$26,940
Less: valuation allowance	-27,170	-26,940
Net future tax assets	0	0
SR&ED expenditures [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	2,195	2,195
Income Tax Loss Carryforwards [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	22,220	21,783
Non Refundable Investment Tax Credit [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	1,719	1,719
Share Issue Cost [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	31	25
Accrued Expenses [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	0	0
Fixed and Intangible Assets [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	1,006	970
Harmonization Credit [Member]	'	'
Income Taxes Future Recovery Disclosure [Line Items]	'	'
Future tax assets gross	$0	$248

Income_Taxes_Income_Tax_Loss_C

Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) (USD $)	12 Months Ended		208 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Tax [Line Items]	'	'	'
Investment tax credits	$0	$0	$1,632
Federal [Member]	'	'	'
Income Tax [Line Items]	'	'	'
SR&ED expenditures (no expiry)	8,283	'	'
Federal [Member] | Year 2014 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	6,089	'	6,089
Federal [Member] | Year 2015 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	11,499	'	11,499
Federal [Member] | Year 2021 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	26	'	26
Investment tax credits	55	'	'
Federal [Member] | Year 2022 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	233	'	233
Investment tax credits	548	'	'
Federal [Member] | Year 2023 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	133	'	133
Investment tax credits	399	'	'
Federal [Member] | Year 2024 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	1,536	'	1,536
Investment tax credits	178	'	'
Federal [Member] | Year 2025 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	4,795	'	4,795
Investment tax credits	199	'	'
Federal [Member] | Year 2026 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	20,562	'	20,562
Investment tax credits	86	'	'
Federal [Member] | Year 2027 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	8,340	'	8,340
Investment tax credits	90	'	'
Federal [Member] | Year 2028 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	10,840	'	10,840
Investment tax credits	50	'	'
Federal [Member] | Year 2029 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	8,502	'	8,502
Federal [Member] | Year 2030 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	2,608	'	2,608
Federal [Member] | Year 2031 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	3,377	'	3,377
Federal [Member] | Year 2018 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Investment tax credits	10	'	'
Federal [Member] | Year 2019 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Investment tax credits	8	'	'
Federal [Member] | Year 2020 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Investment tax credits	96	'	'
Federal [Member] | Year 2032 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	3,491	'	3,491
Federal [Member] | Year 2033 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	1,817	'	1,817
Province State [Member]	'	'	'
Income Tax [Line Items]	'	'	'
SR&ED expenditures (no expiry)	0	'	'
Province State [Member] | Year 2014 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	6,089	'	6,089
Province State [Member] | Year 2015 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	11,499	'	11,499
Province State [Member] | Year 2021 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	0	'	0
Province State [Member] | Year 2022 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	0	'	0
Province State [Member] | Year 2023 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	0	'	0
Province State [Member] | Year 2024 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	1,455	'	1,455
Province State [Member] | Year 2025 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	4,768	'	4,768
Province State [Member] | Year 2026 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	20,496	'	20,496
Province State [Member] | Year 2027 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	8,320	'	8,320
Province State [Member] | Year 2028 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	10,823	'	10,823
Province State [Member] | Year 2029 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	8,502	'	8,502
Province State [Member] | Year 2030 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	2,607	'	2,607
Province State [Member] | Year 2031 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	3,377	'	3,377
Province State [Member] | Year 2032 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	3,491	'	3,491
Province State [Member] | Year 2033 [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income tax loss carryforwards	$1,817	'	$1,817

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details)	12 Months Ended
	Dec. 31, 2013
Canadian Statutoy Income Tax [Member]	'
Income Taxes Disclosure - Additional Information [Line Items]	'
Income Tax Rate	26.50%
Federal Income Tax [Member]	'
Income Taxes Disclosure - Additional Information [Line Items]	'
Income Tax Rate	15.50%
Provincial Income Tax [Member]	'
Income Taxes Disclosure - Additional Information [Line Items]	'
Income Tax Rate	11.00%